De novo design in the cloud from mining big data to clinical candidate
|
|
- Sara Alison York
- 8 years ago
- Views:
Transcription
1 De novo design in the cloud from mining big data to clinical candidate Jérémy Besnard Data Science For Pharma Summit 28 th January 2016
2 Overview the 3 bullet points Cloud based data platform that can efficiently capture and mine multiple data sources Platform to facilitate exchange with collaborators and integrate live data into our infrastructure Large scale machine learning to extract knowledge from this data to improve the decision making during drug discovery campaign
3 Cloud not just a trendy word
4 exscientia A young spin-out company from the University of Dundee Few employees working in multiple locations Built platform from revenues through partnerships and contracts with pharmaceutical companies We were able to work with our partners quickly and efficiently by deploying our infrastructure on the cloud
5 Big data Big compared to what? Philosophy is more important than the size Collect and use all the data rather than use small sample sets Accept messiness of data - benefits of using more data of variable quality outweigh the costs of using small, very exact data Accept we may not need to understand the physical basis of a correlation for the predictions to be useful ex scientia = from knowledge in latin
6 Sources of data Comprehensive exploration Platform integrated with proprietary methods delivers a global view of the polypharmacopaeia HTS & Patent Competitor Structural Fragments Literature derived SAR intel complexes Clinical Proprietary Automated Med-Chem Design Synthesis and Assay through preferred outsourced providers or collaborators
7 Live data Large datasets, public, commercial or corporate are important source of information but once a drug discovery project starts new information is generated and need to be integrated and exploited Learnt from the past but don t live in the past
8 Challenges of data flow - plumbing
9 Shared platform and automation Integration with ScienceCloud from Biovia to share chemistry and assay data with our collaborators Collaborator upload new data Upload to our collaborator for future decisions Automatically downloaded and integrated New information generated
10 DataScience Darwin meets big data Drug discovery is ultimately a high dimensional optimization problem Given the impossibly vast chemical space, brute force searches are inherently inefficient Darwinian processes are unreasonably efficient at finding solutions to high dimensional problems, whether it be evolutionary fitness in nature or drug discovery
11 Initial population selection De novo design algorithm Background knowledge Virtual enumeration Elite & random population selection Non-stop condition Predict properties Multiobjective prioritization Besnard et al. Automated design of ligands to polypharmacological profiles, Nature 492, Final population
12 Illustration of evolution <30 compounds required to discover, synthesize and patent Compound 27s, a selective D4 compound with early lead properties 2 generations 2 generations 2 generations 2 generations 2 generations >10,000 compounds evolved & scored for D4 and off-targets per generation, but only the few most promising compounds were synthesized screened. Compound 27s D4 K i =90nM Patent: PCT/GB2012/ / WO
13 Technology in practice Automated lead generation with rapid design cycle and efficient evolution to drug candidate profile Design Simultaneous design objectives deliver balanced compounds Learn Assay data informs next design cycle Make compounds/cycle High information content Test in disease relevant assays
14 COLLABORATION PROJECTS
15 Metabolic Disorder Dual agonist for two unrelated targets Design against polypharmacology profiles Confirmatory 3D structures of both complexes
16 Bispecific Compounds Goal is to find first-in-class bispecific small molecule bispecific for two enzymes of unrelated families Process: Gather public and patent data to built models De novo design with evolutionary algorithm Docking of top ranked compounds to assess if the compounds could bind in the 2 targets In-vitro assay followed by crystallography
17 Structural validation X-ray crystallography of both structure complexes with the top prioritized compound and assay data confirm the design hypothesis Enzyme A IC 50 = 350nM Enzyme B IC 50 = 10nM
18 Psychiatric Disease Dual agonist for two distinct GPCRs Collaboration with Sumitomo Dainippon Pharma Design against polypharmacology profiles in vitro assessment Rapid delivery of candidate to in vivo safety study
19 Lead Identification Design, synthesis, assay: 5-15 compounds per 2-week cycle Design of 5 chemotypes Compounds synthesized Ease of synthesis Dual agonist activity Best Affinity GPCR selectivity* nm 70 nm to lead optimization nm 100 nm to lead optimization 5 multiple compounds <150nM at both targets. * <50% activity at 1uM over 20 GPCR receptors
20 Lead Optimization 80 further compounds for each prioritized scaffold Dual agonist <20nM target 1 <20nM target 2 scaffold designated as backup scaffold prioritized additional assays progressed further compounds made on this scaffold Candidate Seeking 40 compounds for prioritized scaffold Dual agonist <20nM target 1 <20nM target 2 solubility HERG >10uM GPCR selectivity DMPK
21 quality of compounds over 8 metrics Towards candidate nomination Successful bispecific project for CNS disease 2 chemotypes progressing to candidate selection (for Q2 2015) <400 compounds synthesized and assayed 12 month project circle size number of assays performed for each compound circle colour compound quality/proximity to objectives compounds synthesized over time
22 Faster, cleaner, lower cost Lead to Candidate $3.5M improved productivity $13.5M Hit to Lead Target to Hit Target to Hit Hit to Lead Lead Opt Target Standard cost ($million)* $1 $2.5 $10 Lead to Candidate 1.25 Years shorter timelines enhance efficiency 4.5 Years Hit to Lead Target to Hit Target Standard time (years) * Target to Hit Hit to Lead Lead Opt *Reference cost & time model of R&D process from Eli Lilly: Paul, SM et al. Nature Rev Drug Disc. (2010), 9(3),
23 Disruptive approach Using the cloud as IT infrastructure we were able to develop our technology to mine, process and share information smoothly and efficiently Our technology can use this large set of information to deliver Intellectual Property to our clients in the form of compound designs and improve their hit discovery campaign Multiple targets is a realistic objective
24 Extended capabilities A disruptive system for automated medicinal chemistry Single target projects Improved side effect profiles Planned avoidance of anti-targets Bispecific small molecules Increased efficacy New therapeutic space Efficiency gains Faster project delivery More projects explored Phenotypic drug discovery Increased efficacy New therapeutic space
25 The team CEO Andrew Hopkins Chair of Medicinal Informatics (Dundee & Oxford) Raised $50 Million for research Author of highly cited papers CTO Jérémy Besnard Co-founder & Co-inventor CIO Richard Bickerton Co-founder. 8 years in Biotech. Trained by Sir Tom Blundell. Chemoinformatics Willem van Hoorn Molecular Informatics Adrian Schreyer COO Mark Swindells Previously Yamanouchi (Tsukuba, Japan) & CSO at Inpharmatica Ltd (UK). Raised over 40 Million in Venture Capital Chief Chemist Andy Bell Co-inventor of sildenafil (Viagra) & key contributor to voriconazole (Vfend) project.
26 THANK YOU
STRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS
STRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS Stephen K. Burley Structural GenomiX, Inc. 10505 Roselle Street, San Diego, CA 92121 sburley@stromix.com www.stromix.com Summary Structural
More informationwww.iproteos.com Corporate Presentation November, 2013
www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)
More informationWe use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
More informationHow To Understand The Chemistry Of A 2D Structure
Finding Better Leads using Molecular Fields Sally Rose, Tim Cheeseright, Cresset BioMolecular Discovery Ltd 2D drawings are a ubiquitous representation for molecular structures. Despite this, they provide
More informationAccelerating Lead Generation: Emerging Technologies and Strategies
Brochure More information from http://www.researchandmarkets.com/reports/1057249/ Accelerating Lead Generation: Emerging Technologies and Strategies Description: The number of approvals for new drugs and
More informationDrug Discovery in China
Drug Discovery in China Media Visit to Roche in China Shanghai 30 October 2005 Li Chen, Ph. D. Head of Research, Chief Scientific Officer Roche R&D Center (China) Ltd. Research Business Model in China
More informationThe Open PHACTS Discovery Platform Semantic data integration for Medicinal Chemists
Pharmacoinformatics Research Group Department of Pharmaceutical Chemistry The Open PHACTS Discovery Platform Semantic data integration for Medicinal Chemists Gerhard F. Ecker Dept. of Pharmaceutical Chemistry,
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationAcademic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery
Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery www.pharmacy.unc.edu/cicbdd Stephen V. Frye, Ph.D. University of North Carolina Chapel Hill Outline Why Academic
More informationDiscover more, discover faster. High performance, flexible NLP-based text mining for life sciences
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge
More informationComputational Tools for Medicinal Chemists Increasing the Dimensions of Drug Discovery. Dr Robert Scoffin CEO
Computational Tools for Medicinal Chemists Increasing the Dimensions of Drug Discovery Dr Robert Scoffin CE Agenda > Building Desktop Tools - A History > About Cresset BioMolecular Discovery > Fields,
More informationCheminformatics and Pharmacophore Modeling, Together at Last
Application Guide Cheminformatics and Pharmacophore Modeling, Together at Last SciTegic Pipeline Pilot Bridging Accord Database Explorer and Discovery Studio Carl Colburn Shikha Varma-O Brien Introduction
More informationExploiting the Pathogen box
Exploiting the Pathogen box Dr Richard Gordon Director Strategic Health Innovation Partnerships 9 May 2014 www.ship.mrc.ac.za Background Worked with MMV in many areas Servicing Partner Consultant Collaborator
More informationData Visualization in Cheminformatics. Simon Xi Computational Sciences CoE Pfizer Cambridge
Data Visualization in Cheminformatics Simon Xi Computational Sciences CoE Pfizer Cambridge My Background Professional Experience Senior Principal Scientist, Computational Sciences CoE, Pfizer Cambridge
More informationIntegrating Medicinal Chemistry and Computational Chemistry: The Molecular Forecaster Approach
Integrating Medicinal Chemistry and Computational Chemistry: The Molecular Forecaster Approach Molecular Forecaster Inc. www.molecularforecaster.com Company Profile Founded in 2010 by Dr. Eric Therrien
More informationBuilding a Unified Drug Discovery Database
Building a Unified Drug Discovery Database David M Parry Celltech 11 April 2002 Informatics Challenges with Mergers and Acquisitions 1 Celltech R&D Ltd Leading BioPharmaceutical Company 3 Research Sites
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More informationCheminformatics and its Role in the Modern Drug Discovery Process
Cheminformatics and its Role in the Modern Drug Discovery Process Novartis Institutes for BioMedical Research Basel, Switzerland With thanks to my colleagues: J. Mühlbacher, B. Rohde, A. Schuffenhauer
More informationMedicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
More informationCorporate Overview. Dr Robert Scoffin CEO. http;//www.re-pharm.com/ STAND NUMBER: 27 rob@re-pharm.com
Corporate Overview Dr Robert Scoffin CEO http;//www.re-pharm.com/ STAND NUMBER: 27 rob@re-pharm.com Re-Pharm Summary > Focus on commercially valuable early stage assets. > Repositioned compounds > Using
More informationAlterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD
Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD 1 Summary Hypothesis Generation Candidate Development Commercialization Target Identification
More informationTIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More informationMSC IN MEDICINAL CHEMISTRY
faculty of health and medical sciences university of copenhagen MSC IN MEDICINAL CHEMISTRY det sundhedsvi københavns univer Master s programme at the University of Copenhagen msc in medicinal chemistry
More informationNew Tools. Diseases. for Research on. R&D for Neglected Patients. Scientific Symposium. conference programme. In collaboration with.
Wednesday, 4 December 2013 Institut Pasteur, Paris, France R&D for Neglected Patients Scientific Symposium New Tools for Research on Kinetoplastid Diseases conference programme Speakers & chairs Scientific
More informationFrom Data to Foresight:
Laura Haas, IBM Fellow IBM Research - Almaden From Data to Foresight: Leveraging Data and Analytics for Materials Research 1 2011 IBM Corporation The road from data to foresight is long? Consumer Reports
More informationDriving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics
Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics John D Antonio Practice Leader, Licensing & Competitive Intelligence About Paragon We help increase asset value from
More informationTHOMSON REUTERS CORTELLIS FOR INFORMATICS. REUTERS/ Aly Song
THOMSON REUTERS CORTELLIS FOR INFORMATICS REUTERS/ Aly Song THOMSON REUTERS CORTELLIS FOR INFORMATICS 1 Table of Contents Table of Contents...1 The challenge... 2 The solution... 2 WHAT CAN YOU DO WITH
More informationLead generation and lead optimisation:
Lead generation and lead optimisation: the value of linking HT co-structure analysis and HT chemistry The coupling of High Throughput co-structure analysis with focused library generation is not only proving
More informationNetherlands escience Center
Netherlands escience Center ICT Synergy Hub, Amsterdam Research & Innovation in the Big Data Era CWI in Bedrijf Centrum Wiskunde & Informatica Op 5 oktober 2012 Prof. dr. Jacob de Vlieg ¹ ² 1. CEO & Scientific
More informationPivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform
PRESS RELEASE Pivot Park Screening Centre participates in novel 196 million pan-european drug discovery platform Pivot Park Screening Centre in Oss will play an important role in a new pan-european drug
More informationCall 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
More informationPIRAMAL DISCOVERY SOLUTIONS
PIRAMAL DISCOVERY SOLUTIONS Pharma Solutions products and services Delivering Globally Integrated Solutions across the drug lifecycle We are the Contract Development & Manufacturing arm of Piramal Healthcare,
More informationMatteo di Tommaso FDA-PhUSE March 2013 Vice President, Research Business Technology Chair, PRISME Forum
Pharma R&D IT & The Cloud Matteo di Tommaso FDA-PhUSE March 2013 Vice President, Research Business Technology Chair, PRISME Forum This presentation outlines a general technology direction. Pfizer Inc has
More informationBIOINFORMATICS Supporting competencies for the pharma industry
BIOINFORMATICS Supporting competencies for the pharma industry ABOUT QFAB QFAB is a bioinformatics service provider based in Brisbane, Australia operating nationwide and internationally. QFAB was established
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationThe INFUSIS Project Data and Text Mining for In Silico Modeling
The INFUSIS Project Data and Text Mining for In Silico Modeling Henrik Boström 1,2, Ulf Norinder 3, Ulf Johansson 4, Cecilia Sönströd 4, Tuve Löfström 4, Elzbieta Dura 5, Ola Engkvist 6, Sorel Muresan
More informationUse of Predictive ADME in Library Profiling and Lead Optimization
Use of Predictive ADME in Library Profiling and Lead Optimization Osman F. Güner and Robert D. Brown 223 rd ACS National Meeting April 2002, Orlando Florida Why Predictive ADME in Early Discovery? The
More informationEVT Execute & EVT Innovate Leading drug discovery
EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking
More informationBROMOscan Quantitative Ligand Binding Assays
BROMOscan Quantitative Ligand Binding Assays Identification of Best In Class Bromodomain Inhibitors Elizabeth Quinn, PhD Director, LeadHunter Discovery Services Outline Introduction Challenges to Epigenetic
More informationNew epigenetic agents: therapeutic approach in cancer
New epigenetic agents: therapeutic approach in cancer Madrid, 2 de julio de 2014 Outline Institution: CIMA Project Partnering Opportunities 2 WHAT IS CIMA? CIMA The Center for Applied Medical Research
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More informationInformatics and Knowledge Management at the Novartis Institutes for BioMedical Research (NIBR)
Informatics and Knowledge Management at the Novartis Institutes for BioMedical Research (NIBR) Enable Science in silico & Provide the Right Knowledge to the Right People at the Right Time to enable the
More informationValidated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies
Validated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies Abhishek Saharia, Ph. D. Senior Product Manager Validation Assays Drug Discovery Evolution
More informationDrug design Drug repositioning Virtual screening
Drug design Drug repositioning Virtual screening May 2013 Plebiotic services Drug design & re-design Drug repositioning Virtual screening Homology modeling Library generation (combinatorial chemistry)
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationHow To Understand Protein-Protein Interaction And Inhibitors
Protein-Protein Interactions and Inhibitors Alan Naylor Independent Consultant Optibrium Consultants Meeting Cambridge 27 th November 2012 Why PPI inhibitors? PPIs are involved in many biological / disease
More information19 October 2006. Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009. By email; announcements@bsx.com.
19 October 2006 Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009 By email; announcements@bsx.com.au RE: Announcement by State Development Fund Limited Please
More informationA career on the science park
A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort
More informationTransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet
TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating
More informationBBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS
BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS 1. The Technology Strategy sets out six areas where technological developments are required to push the frontiers of knowledge
More informationTHE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE (CCDC)
ABOUT THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE (CCDC) The CCDC is the trusted research institution responsible for the 50-year old Cambridge Structural Database (CSD) and its applications. Used by thousands
More informationBig Data in Drug Discovery
Big Data in Drug Discovery David J. Wild Assistant Professor & Director, Cheminformatics Program Indiana University School of Informatics and Computing djwild@indiana.edu - http://djwild.info Epochs in
More informationMaking semantics work in drug discovery
Indiana University School of Informatics and Computing Making semantics work in drug discovery Information is cheap. Understanding is expensive (Karl Fast) David Wild, Assistant Professor and Director,
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationStrategies and tactics for optimizing the Hit-to-Lead process and beyond A computational chemistry perspective
In pharmaceutical discovery, Hit-to-Lead strategies and processes are rapidly evolving and yet far from mature. A computational chemistry perspective can help projects deal with discovery risks and probabilities,
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationFragment-based lead generation of reversible inhibitors for lysine-specific demethylases
Fragment-based lead generation of reversible inhibitors for lysine-specific demethylases www.beactica.com Ulf Bremberg CSO Beactica AB Drug Discovery 2015 Elrig 3 Sept 2015 Presentation overview Beactica
More informationH1 2013 Innovation. efficiency
H1 2013 Innovation efficiency on track Evotec AG, H1 2013 Interim Report, 08 August 2013 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which
More informationThe Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results.
The Aptuit Center for Drug Discovery & Development Verona, Italy Uncommon Expertise. Exceptional Results. 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise,
More informationMolecular descriptors and chemometrics: a powerful combined tool for pharmaceutical, toxicological and environmental problems.
Molecular descriptors and chemometrics: a powerful combined tool for pharmaceutical, toxicological and environmental problems. Roberto Todeschini Milano Chemometrics and QSAR Research Group - Dept. of
More informationOpen PHACTS Workshop, February 2015. The Lilly Perspective: Challenges We Face & Tools We Need
Open PHACTS Workshop, February 2015 The Lilly Perspective: Challenges We Face & Tools We Need María Jesús Blanco, Ph.D. Director, Advanced Portfolio Strategies Marta Piñeiro-Núñez, Ph.D. Director, Open
More informationComputational Drug Repositioning by Ranking and Integrating Multiple Data Sources
Computational Drug Repositioning by Ranking and Integrating Multiple Data Sources Ping Zhang IBM T. J. Watson Research Center Pankaj Agarwal GlaxoSmithKline Zoran Obradovic Temple University Terms and
More informationPredictive Analytics Certificate Program
Information Technologies Programs Predictive Analytics Certificate Program Accelerate Your Career Offered in partnership with: University of California, Irvine Extension s professional certificate and
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationData Warehouse Design for Pharmaceutical Drug Discovery Research
Data Warehouse Design for Pharmaceutical Drug Discovery Research Melinda G. Axel and Il-Yeol Song College of Information Science and Technology, Drexel University, Philadelphia., PA, 19104 U.S.A. email:
More informationA vaccine for rheumatoid arthritis
A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationAgenda Item 3. Discovery to Product Accelerator
Agenda Item 3 Discovery to Product Accelerator BOARD OF REGENTS SUMMARY OF ITEM FOR ACTION INFORMATION OR DISCUSSION TOPIC: Discovery to Product Accelerator (information item) COMMITTEE: Economic Development
More informationBuilding innovative drug discovery alliances. Profitable. Growth Go
Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationDMPK: Experimentation & Data
DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students
More informationMaking the most of academic drug target discoveries
Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies
More informationRecord 16.9m for Oxford spinout designing stem cell drugs to treat age- related disease
Record 16.9m for Oxford spinout designing stem cell drugs to treat age- related disease May 10 2016 One of the most ambitious Oxford spinouts to date is on route to becoming a powerhouse in age- related
More informationMYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME
FOR IMMEDIATE RELEASE MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME - $185 Million Collaboration to Determine All Human Protein Interactions And Decipher Biochemical Pathways
More informationThe Leading Gene Through Screen CRO
The Leading Gene Through Screen CRO Molecular Biology Services Molecular Biology drives modern drug discovery. Drug screening, target validation and structural biology processes frequently require recombinant
More informationMarubeni & Biotech Business
Marubeni & Biotech Business Hiro MATSUBARA Silicon Valley Branch Marubeni Corporation April, 2006 Founded: 1858 during Shogun era Head Office: Tokyo, Japan Paid-in Capital: Jpn Yen 570 Billion (US $4.8
More informationTechnology and Expertise Add Operational Value to Medical Device Trials
Technology and Expertise Add Operational Value to Medical Device Trials Copyright 2015 Medidata Solutions. Medidata Solutions and other trademarks reserved in the US and globally. Medidata and other marks
More informationGenScript USA Inc. Open Position List
GenScript USA Inc. is a world leader in developing and marketing innovative biotechnology products. Our dedication to innovation has led GenScript to generate a continuous flow of services and products
More informationCloud-based Informatics Systems for Collaborative Network Research in Life Sciences
White Paper Cloud-based Informatics Systems for Collaborative Network Research in Life Sciences Robert D Brown, Ph.D November 2015 White Paper: Cloud-based Informatics Systems Growth in external spending
More informationOutsourcing life science informatics solutions
Outsourcing life science:outsourcing life science 19/4/07 18:51 Page 29 Outsourcing life science informatics solutions The life science industry depends on information gathered from new technologies for
More informationConsensus Scoring to Improve the Predictive Power of in-silico Screening for Drug Design
Consensus Scoring to Improve the Predictive Power of in-silico Screening for Drug Design Masato Okada Faculty of Science and Technology, Masato Tsukamoto Faculty of Pharmaceutical Sciences, Hayato Ohwada
More informationBig Data An Opportunity or a Distraction? Signal or Noise?
Big Data An Opportunity or a Distraction? Signal or Noise? Maya R. Said, Sc.D. SVP & Global Head, Oncology Policy & Market Access, Novartis 3rd International Systems Biomedicine Symposium Luxembourg, 28
More informationMRC Technology Centre for Therapeutics Discovery
MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established
More informationCDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis
CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society
More informationTowards Well-Defined ADCs (Antibody Drug Conjugates)
Towards Well-Defined ADCs (Antibody Drug Conjugates) Next generation approach June 10, 2015 Dr. Yong Zu Kim, CEO and President LegoChem Biosciences, Inc. Antibody Drug Conjugates ADC binds to Antigen Endocytosis
More informationForward step pby step with Action Plan 2016
Forward step pby step with Action Plan 2016 Evotec AG, Full-Year Results 2012, Frankfurt/Main, 26 March 2013 Forward-looking statements Information set forth in this presentation contains forward-looking
More informationComputational Chemistry and Cheminformatics in Drug Discovery Research
Computational Chemistry and Cheminformatics in Drug Discovery Research Bioinformatics X3, Uppsala Feb 9 2009 Mats Kihlén Head of Research Informatics inovacia AB, Sweden mats.kihlen@inovacia.se Overview
More informationCombinatorial Chemistry and solid phase synthesis seminar and laboratory course
Combinatorial Chemistry and solid phase synthesis seminar and laboratory course Topic 1: Principles of combinatorial chemistry 1. Introduction: Why Combinatorial Chemistry? Until recently, a common drug
More informationCreative Utilization of Existing Knowledge to Harness Innovation for the Neglected
Creative Utilization of Existing Knowledge to Harness Innovation for the Neglected Els Torreele, PhD Senior Project Manager Drugs for Neglected Diseases initiative Best Science for the Most Neglected Stakeholders
More informationUniversity of Michigan College of Pharmacy Department of Medicinal Chemistry. Eleventh Annual Leroy B. Townsend Lectureship in Medicinal Chemistry
University of Michigan College of Pharmacy Department of Medicinal Chemistry Eleventh Annual Leroy B. Townsend Lectureship in Medicinal Chemistry Leah N. Makley, Ph.D. Chief Scientific Officer, Director
More informationPutting IBM Watson to Work In Healthcare
Martin S. Kohn, MD, MS, FACEP, FACPE Chief Medical Scientist, Care Delivery Systems IBM Research marty.kohn@us.ibm.com Putting IBM Watson to Work In Healthcare 2 SB 1275 Medical data in an electronic or
More informationFlorida Translational Research Program (FTRP)
Florida Translational Research Program (FTRP) Solicitation of Concept / Assay Development (CAD) Projects for use in Pre-Therapeutic Discovery via High-Throughput Screening (HTS) Purpose of the Program
More informationusing the fully human ADLib system
Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is
More informationBuilding Bridges to Long-Term Growth
N o 7 Building Bridges to Long-Term Growth Tanabe is working to realize its corporate philosophy of contributing to people over the world desiring to live healthy and securely through pharmaceuticals and
More informationChemical safety and big data: the industry s demands
Chemical safety and big data: the industry s demands Richard CURRIE Senior Technical Expert; Group Leader & Global Predictive and Computational Toxicology Lead Valid results Useful results Credit Money/Grants
More informationHow to create and interpret the predictive analysis of a compound
How to create and interpret the predictive analysis of a compound Platform with suite of tools Predict & understand biological effects of small molecules & compounds Predict targets and metabolites, potential
More informationA UNIFIED VIEW OF RESEARCH AND TRIAL DATA Red Hat JBoss Data Virtualization for the pharmaceutical and life sciences industry
A UNIFIED VIEW OF RESEARCH AND TRIAL DATA Red Hat JBoss Data Virtualization for the pharmaceutical and life sciences industry TECHNOLOGY OVERVIEW UNLOCK THE FULL POTENTIAL OF ALL THE DATA ASSETS TO DRIVE
More informationHitting the New Accelerated Pace of Digital Asset Management
Issues Topics Awards Resources News Market News Log In Register Search Tools Order Reprints or Eprints Download article as PDF James Brown Hitting the New Accelerated Pace of Digital Asset Management Previous
More information